BG Medicine Goes Public, Begins Trading on Nasdaq | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BG Medicine today began trading shares of its stock on the Nasdaq under ticker symbol "BGMD."

The company is offering 5 million shares of its stock at $7 per share, for potential proceeds of $35 million. Lazard Capital Markets is serving as the sole book-running manager for the offering. Baird and Cowen and Company are co-managers.

The underwriters have a 30-day option to purchase up to 750,000 shares to cover over-allotments, if any.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for RNA splicing in genetic variation, and more.

An advocacy group sues the US Food and Drug Administration over redactions of information about advisory committee members, Stat News reports.

Mexico is trying to lure young genomics researchers back home with their own labs, Science reports.

A molecular autopsy has aided a woman's search for why sudden cardiac death has stalked her family, the Wall Street Journal reports.